RhoVac strengthens management by appointing Anders Månsson as Chief Business Officer (CBO) and deputy CEO
RhoVac AB ("RhoVac") announces today, 8 March 2019, that the company recruits Anders Månsson as Chief Business Officer (CBO) and deputy CEO to lead the ongoing activities in business development.
The company has recruited Anders Månsson as Chief Business Officer (CBO) and deputy CEO to the management team, with responsibility for business development and communication. RhoVac strengthens the management team to ensure that the company has the right expertise and experience for the ongoing business development that is in parallel to further development of RhoVac's drug candidate RV001- treatment for metastatic cancer.
Anders Månsson holds a Bachelor of Science in Business Administration and Economics from Lund University and an MBA from the Business School Lausanne, Switzerland. Anders has long and solid experience in M&A, licensing and business development at a global level from LEO Pharma and Ferring Pharmaceuticals. In recent years, Anders has been on several positions including Industrial Advisor in Life Sciences to Ratos AB, Chairman of CanImGuide Therapeutics AB, board member of Respiratorius AB and EQL Pharma as well as CEO and partner of Longboat Amniotics.
Anders Månsson comments:
-With the drug candidate RV001 ready for clinical phase IIb, I see that RhoVac is now entering a stage where business development and partnerships will play an increasingly important role for the company's success. With my background and experience from this field, I therefore believe I can make a positive contribution to company's future development.
CEO Anders Ljungqvist comments:
-I look forward to the cooperation with Anders Månsson. Anders will strengthen and support the current management team’s profile by providing years of solid experience and expertise for the ongoing development of the company. A warm welcome to Anders from RhoVac!
For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 8th March 2019.
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published I August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Trade Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.